Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Aphria Inc. APHA

Aphria, which is headquartered in Ontario, produces and sells medicinal and recreational cannabis. The company operates through retail and wholesale channels in Canada and internationally. Aphria is a main distributor of medical cannabis to Germany and has operations in over 10 countries outside of Canada. However, it does not have exposure to the U.S. CBD or THC markets due to the constraints of federal prohibition. It has some U.S. exposure through the acquisition of SweetWater, a craft brewer


NDAQ:APHA - Post by User

Comment by Savage97on May 12, 2020 4:28pm
282 Views
Post# 31019072

RE:When all is laid out in front of you.

RE:When all is laid out in front of you. Great post.  Found a post explaining Aphria's inventory taken from their financials:  Total inventory value of $225,832,000 $40,252,000 is distribution inventory $22,601,000 is other inventory (vape pens, packaging etc) The rest at approximately $160,000,000 is cannabis in various forms.

The large increase is due to DD cannabis that was harvested, but wasn’t ready to be sold until our current quarter of March-May. I believe we recognized our first sales in early March.

Edit- during their conference call they mentioned sales from CC Pharma were up 15% due to Covid-19. Medical sales up 18%. Pulled guidance due to concerns over Covid-19 and not knowing if it would have a material impact, especially in Europe.

At the end of April Carl did a Fireside chat and stated that we have not seen any material impacts at Aphria due to Covid-19.

<< Previous
Bullboard Posts
Next >>